Biogen BIIB Contract manufacturing, royalty and other revenue — Total Revenue

Other product segments

Similar metrics at other companies

LGNDContract revenue and other income — Total revenues and other income

$110K-97.5%

CRMDContract revenue — Total Revenue

$5.51M—

LGNDContract revenue — Total revenues and income

$110K-97.5%

LGNDContract revenue and income — Total revenues and income

$110K-97.5%

MRAMLicensing, royalty, patent, engineering services and other revenue — Total Revenue

$772K-63.4%

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

Questions, answered.

What is Biogen's contract manufacturing, royalty and other revenue — total revenue?

Biogen (BIIB) reported contract manufacturing, royalty and other revenue — total revenue of $246.9M in Q1 2026.

How has Biogen's contract manufacturing, royalty and other revenue — total revenue changed year-over-year?

Biogen's contract manufacturing, royalty and other revenue — total revenue decreased by 15.8% year-over-year, from $293.3M to $246.9M.

What does contract manufacturing, royalty and other revenue — total revenue mean?

This metric represents the aggregate revenue generated from contract manufacturing services, intellectual property royalties, and miscellaneous ancillary business activities. It captures income streams that are distinct from the company's primary direct product sales, reflecting the monetization of manufacturing capacity and proprietary technology assets. This segment provides insight into the company's ability to leverage its infrastructure and R&D portfolio to generate diversified, non-core income.